11 17
1 15 15 11 3a
19 19 49 19 19 18

2c Andrea Facciabene, PhD

1 19 19 31 19 65 19 19 49 31 31 19 19 19 19 19 45
3b
19 19 19 1 1 1 1 2d
7f Andrea Facciabene photo 2f
4c

Research Associate Professor of Radiation Oncology

18

74 Department: Radiation Oncology

11 13
7
1 1 5
1 18
e
25

Contact Information

c

5a University of Pennsylvania Perelman School of Medicine
28 Department of Radiation Oncology
3a Smilow Center for Translational Research Rm. 8-133
7c 3400 Civic Center Blvd., Bldg 421
Philadelphia, PA 19104 e7
Office: 215-746-7071
Fax: 215-898-0090
Email: Andrea.Facciabene@pennmedicine.upenn.edu

13
5 e
1e

Publications

5f

Pubmed Link

b
9 e 9 12
1b

Education

d
    1d
  • 5d BS (Pharmaceutical Biotechnology Science (summa cum laude)) a5
    University of Bologna, Bologna, Italy (Thesis: Centre of Drug Discovery, L'Aquila, Italy) Summa Cum Laude, 2000
    • 1d
  • 46 PhD (Molecular and Cellular Biology) c0
    University of Perugia, Perugia, Italy. In collaboration with the Univ of California San Diego, San Diego, CA (coursework 11/01-5/06), 2006
    • 1a
b
b
1 5
1 1 1 2b

Description of Research Expertise

1d7

Dr. Andrea Facciabene is at the forefront of cancer immunotherapy research, leading a dynamic laboratory that seamlessly integrates basic scientific exploration with clinical investigation. His research is dedicated to unraveling the intricate network of immune responses in the context of cancer, with a dual mission: to advance our comprehension of tumor immunology and to translate these groundbreaking insights into highly effective therapeutic strategies.
8
1c4 The Facciabene laboratory has made significant strides in the development of innovative approaches for cancer therapy. These include cutting-edge investigations studying the vital role played by the gut microbiota in regulating anticancer immune responses. This groundbreaking work seeks to illuminate the intricate interplay between the gut microbiome and cancer radiation and immune therapy, offering new avenues for therapeutic intervention.
8
201 Our research team has been developing two innovative vaccination strategies in the field of cancer immunotherapy. The first strategy involves harnessing the potential of mitochondrial DNA mutations, known as TAMAs, by using mitochondria isolated from tumor cells. The second approach focuses on emerging tumor vasculature antigens. These pioneering vaccination methods have the potential to revolutionize cancer treatment by mobilizing the body's immune system to target and combat malignancies effectivel
8
8
167 Complementing the laboratory's basic research, clinical investigations are dedicated to the development of preclinical immunotherapies. These translational efforts bridge the gap between scientific discovery and real-world patient care, with the ultimate goal of bringing innovative and effective immunotherapies to the forefront of cancer treatment.
8
5

1 1 1 1 1f

Selected Publications

5
    5
  • 14a Hwang D, Erdman MC, Adhikari S, Pantula R, Epstein K, Li P, Costabile F, Rotsides P, Wang CS, Sun SM, Fazelinia H, Spruce LA, Fugmann T, Rrustemi T, Soh WT, Farrel A, Want MY, Facciabene A, Mir M, Maris JM, Sgourakis NG : HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors 36 Sci Adv 12(1) : eaeb0821, Jan 2026
    • 5
  • 1dd Feigenberg SJ, Costabile F, Tanes C, Bittinger K, O'Connor R, Agarwal D, Skoufos G, Salaris S, Hatzigeorgiou A, Kostopoulos N, Lloyd S, Friedes C, Chen L, Yegya-Raman N, Cengel K, Levin W, Valentić B, Quarton T, Shestov AA, Berman A, Bradley J, Maity A, Koumenis C, Ben-Josef E, Facciabene A. : Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. 7 44 J Immunother Cancer. 13(7) : e011356, Jul 2025
    • 5
  • ec Urias E, Lee J, Weil CR, Roach E, Lloyd S, Hashibe M, Facciabene A, Maity A, Tao R. : Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: a meta-analysis of prospective clinical trials. 7 38 BMJ Oncol. 4(1) : e000732, May 2025
    • 5
  • 10b Costabile F, George S, Facciabene A, Filaci G, Mastrogiacomo M : An early-stage 3D fibroblast-featured tumor model mimics the gene expression of the naïve tumor microenvironment, including genes involved in cancer progression and drug resistance 36 Front Oncol 15 : 1572315, Oct 2025
    • 5
  • 138 Kostopoulos N, Costabile F, Krimitza E, Beghi S, Goia D, Perales-Linares R, Thyfronitis G, LaRiviere MJ, Chong EA, Schuster SJ, Maity A, Koumenis C, Plastaras JP, Facciabene A : Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. 7 69 Blood Adv. 8(24) : 6308-6320, Dec 2024 Notes: doi: 10.1182/bloodadvances.2024012599.
    • 5
  • 29a Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. : Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. 79 Nat Med. doi: 10.1038/s41591-022-02069-7 Nov;29(11):2954. 2023 Notes: Co-Last and Co-Corresponding
    • 5
  • 169 Perales-Linares R, Leli NM, Mohei H, Beghi S, Rivera OD, Kostopoulos N, Giglio A, George SS, Uribe-Herranz M, Costabile F, Pierini S, Pustylnikov S, Skoufos G, Barash Y, Hatzigeorgiou AG, Koumenis C, Maity A, Lotze MT, Facciabene A : Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance. 7 40 Cancer Research 83(21) : 3562-3576, Nov 2023
    • 5
  • 7a Amit U, Facciabene A, Ben-Josef E. : "Radiation Therapy and the Microbiome; More Than a Gut Feeling." 37 Cancer J. 29(2) : 84-88, April 2023
    • 5
  • 1d9 Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, George SS, Pierini S, Krimitza E, Costabile F, Ghilardi G, Amelsberg KV, Lee YG, Pajarillo R, Markmann C, McGettigan-Croce B, Agarwal D, Frey N, Lacey SF, Scholler J, Gabunia K, Wu G, Chong E, Porter DL, June CH, Schuster SJ, Bhoj V, Facciabene A. : Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy 41 Molecular Therapy 31(3) : 686-700, March 2023
    • 5
  • 14e Yegya-Raman N, Wright CM, LaRiviere MJ, Baron JA, Lee DY, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Maity A, Facciabene A, Paydar I, Plastaras JP : Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy 43 Clin Transl Radiat Oncol. 39 : 100587, Jan 2023
    • 6
1 1 19 1b
11 15 11 15 25 11 11 11 18
9 13